237 related articles for article (PubMed ID: 2769847)
61. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
62. Bacillus Calmette-Guerin immunotherapy of infiltrating bladder cancer.
Netto NR; Lemos GC
J Urol; 1984 Oct; 132(4):675-7. PubMed ID: 6471211
[TBL] [Abstract][Full Text] [Related]
63. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
Sosnowski JT
Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
[No Abstract] [Full Text] [Related]
64. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
[TBL] [Abstract][Full Text] [Related]
65. Immunotherapy with bacille Calmette-Guérin in patients with superficial transitional cell carcinoma of the bladder associated with bilharziasis.
Wishahi MM; Ismail IM; el-Sherbini M
Br J Urol; 1994 Jun; 73(6):649-54. PubMed ID: 8032832
[TBL] [Abstract][Full Text] [Related]
66. Intravesical bacillus Calmette-Guerin for patients with high-risk superficial bladder cancer.
Klimberg IW; Pow-Sang JM; Cartwright CK; Wajsman Z
Urology; 1991 Feb; 37(2):180-4. PubMed ID: 1992591
[TBL] [Abstract][Full Text] [Related]
67. Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer.
Onur O; Celiker R
Clin Rheumatol; 1999; 18(1):74-6. PubMed ID: 10088958
[TBL] [Abstract][Full Text] [Related]
68. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
Miyazaki J; Onozawa M; Takaoka E; Yano I
Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
[TBL] [Abstract][Full Text] [Related]
69. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin.
Deresiewicz RL; Stone RM; Aster JC
J Urol; 1990 Dec; 144(6):1331-3; discussion 1333-4. PubMed ID: 2231918
[TBL] [Abstract][Full Text] [Related]
70. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Witjes JA; vd Meijden AP; Debruyne FM
Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
[TBL] [Abstract][Full Text] [Related]
71. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.
Cookson MS; Sarosdy MF
J Urol; 1992 Sep; 148(3):797-801. PubMed ID: 1512829
[TBL] [Abstract][Full Text] [Related]
72. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
73. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
74. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
75. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
76. [Intravesical Calmette-Guérin bacillus therapy of bladder tumors].
Uchida T; Muruyama M; Igarashi M; Kobayashi K; Mashimo S; Ishibashi A; Koshiba K; Shibuya M
Nihon Hinyokika Gakkai Zasshi; 1987 Dec; 78(12):2087-97. PubMed ID: 3451983
[No Abstract] [Full Text] [Related]
77. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
Eure GR; Cundiff MR; Schellhammer PF
J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
[TBL] [Abstract][Full Text] [Related]
78. Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin or adriamycin. Results of long-term follow-up.
Khanna OP; Son DL; Son K; Mazer H; Read J; Nugent D; Cottone R; Heeg M; Rezvan M; Uhlman R
Urology; 1991 Sep; 38(3):271-9. PubMed ID: 1887543
[TBL] [Abstract][Full Text] [Related]
79. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain.
Kamat MR; Kulkarni JN; Tongaonkar HB; Dalal AV
J Urol; 1994 Nov; 152(5 Pt 1):1424-8. PubMed ID: 7933175
[TBL] [Abstract][Full Text] [Related]
80. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
